390
Participants
Start Date
December 12, 2018
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Olaparib
Olaparib 300 mg administered BID as two, 150 mg oral tablets.
Hopitaux Universitaires de Geneve HUG. ( Site 1406), Geneva
Kinghorn Cancer Centre ( Site 2200), Darlinghurst
Rigshospitalet ( Site 0402), Copenhagen
MNCCI Port Macquarie Base Hospital ( Site 2201), Port Macquarie
Herlev og Gentofte Hospital. ( Site 0401), Herlev
Odense Universitetshospital ( Site 0400), Odense
Linear Clinical Research Ltd ( Site 2202), Nedlands
Ospedale Regionale di Bellinzona e Valli ( Site 1407), Bellinzona
Universitaetsspital Zuerich ( Site 1400), Zuerich
VA New York Harbor Healthcare System Manhattan ( Site 0094), New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057), New York
Memorial Sloan Kettering Cancer Center ( Site 0026), New York
Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126), Harrison
Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102), Trujillo
Seoul National University Bundang Hospital ( Site 2402), Seongnam-si
Hospital Nacional Guillermo Almenara Irigoyen ( Site 3107), Lima
Clinica Internacional Sede San Borja ( Site 3100), Lima
Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 3101), Lima
Oncosalud-Clinical Research ( Site 3108), Lima
Instituto Nacional de Enfermedades Neoplasicas ( Site 3106), Lima
Hospital Central de la Fuerza Aerea del Peru ( Site 3104), Lima
Hospital Militar Central Coronel Luis Arias Schereiber ( Site 3105), Lima
Hospital Arzobispo Loayza ( Site 3103), Lima
Eastern Regional Medical Center, Inc. ( Site 0077), Philadelphia
Istituto Clinico Humanitas Research Hospital ( Site 0703), Rozzano
Centre Georges Francois Leclerc ( Site 0608), Dijon
University of Maryland ( Site 0050), Baltimore
Weinberg Cancer Institute at Franklin Square ( Site 0054), Baltimore
Trakya Universitesi Tip Fakultesi ( Site 1500), Edirne
Hospital Universitario Quiron Madrid ( Site 1352), Pozuelo de Alarcón
Augusta University ( Site 0028), Augusta
Centro Estatal de Cancerologia de Chihuahua ( Site 2907), Chihuahua City
Institut Bergonie ( Site 0603), Bordeaux
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1505), Istanbul
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1506), Istanbul
Ege Universitesi Tip Fakultesi ( Site 1502), Izmir
Markey Cancer Center ( Site 0018), Lexington
Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1507), Konya
Actualidad Basada en la Investigacion del Cancer ( Site 2903), Guadalajara
Henry Ford Health System ( Site 0060), Detroit
Policlinico Le Scotte di Siena ( Site 0704), Siena
Sanford Hematology Oncology-Sioux Falls SD ( Site 0012), Sioux Falls
Unidad Biomedica Avanzada Monterrey S. A. ( Site 2902), Monterrey
Institut de Cancerologie Strasbourg Europe ( Site 0613), Strasbourg
Oaxaca Site Management Organization S.C. ( Site 2905), Oaxaca City
Cancer Partners of Nebraska ( Site 0051), Lincoln
Southwestern Regional Medical Center, Inc. ( Site 0079), Tulsa
Cuidados Oncologicos ( Site 2908), Santiago de Quetaro
Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092), Aurora
Istituto Nazionale Tumori Fondazione Pascale ( Site 0700), Napoli
Intermountain Healthcare ( Site 0043), St. George
The University of Arizona Cancer Center - North Campus ( Site 0011), Tucson
CHU Poitiers ( Site 0612), Poitiers
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 2901), Madero
Cedars Sinai Medical Center ( Site 0002), Los Angeles
St Joseph Heritage Healthcare-Oncology ( Site 0056), Fullerton
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007), San Francisco
Institut Gustave Roussy ( Site 0601), Villejuif
Virginia Mason Medical Center ( Site 0052), Seattle
Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093), Seattle
Administradora Country SA - Clinica del Country ( Site 2802), Bogotá
Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2807), Bogotá
Instituto Nacional de Cancerologia E.S.E ( Site 2809), Bogotá
N.N. Blokhin NMRCO ( Site 1201), Moscow
MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1213), Moscow
MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216), Krasnogorsk
Arkhangelsk Clinical Oncological Dispensary ( Site 1204), Arkhangelsk
Clinical Hospital Saint Luka ( Site 1205), Saint Petersburg
SBHI Leningrad Regional Clinical Hospital ( Site 1206), Saint Petersburg
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1208), Saint Petersburg
Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2808), Valledupar
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103), Craiova
Oncomedica S.A. ( Site 2806), Montería
Ryazan Regional Clinical Oncology dispensary ( Site 1202), Ryazan
Medisprof ( Site 1107), Cluj-Napoca
SC Radiotherapy Center Cluj SRL ( Site 1105), Comuna Floresti
S.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102), Oradea
Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 120, Kazan'
SBHI Samara Regional Clinical Oncology Dispensary ( Site 1211), Samara
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1212), Chelyabinsk
Spitalul PDR Medlife ( Site 1106), Brasov
C. Medico Imbanaco Cali S.A. ( Site 2810), Santiago de Cali
National Cancer Center Hospital East ( Site 2600), Kashiwa
Rambam Health Care Campus-Oncology Division ( Site 0801), Haifa
Chaim Sheba Medical Center ( Site 0803), Ramat Gan
Sourasky Medical Center ( Site 0804), Tel Aviv
Soroka Medical Center ( Site 0800), Beersheba
Hadassah Ein Kerem Medical Center ( Site 0802), Jerusalem
Winship Cancer Institute of Emory University ( Site 0025), Atlanta
University of Massachusetts ( Site 0017), Worcester
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0116), Middletown
Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 2703), Berazategui
Hospital Britanico de Buenos Aires ( Site 2704), Ciudad de Buenos Aires
Instituto de Investigaciones Metabolicas ( Site 2700), Buenos Aires
Hospital Aleman ( Site 2702), Buenos Aires
Sunnybrook Research Institute ( Site 0210), Toronto
Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0203), Montreal
Jewish General Hospital ( Site 0209), Montreal
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0, Québec
Fundacion Centro de Investigacion Clinica CIC ( Site 2812), Medellín
Rodrigo Botero SAS ( Site 2801), Medellín
Biomelab S A S ( Site 2800), Barranquilla
Centre Antoine Lacassagne ( Site 0610), Nice
Centro Regional de Sub Especialidades Medicas SA ( Site 3003), Guatemala
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 3004), Guatemala City
Integra Cancer Institute ( Site 3006), Guatemala City
Grupo Angeles SA ( Site 3001), Guatemala City
Mater Misericordiae University Hospital ( Site 1654), Dublin
Bon Secours Hospital ( Site 1656), Cork
St. Vincent's University Hospital ( Site 1653), Dublin
Tallaght University Hospital ( Site 1652), Dublin
Aichi Cancer Center Hospital ( Site 2602), Nagoya
Kyoto University Hospital ( Site 2603), Kyoto
Osaka University Hospital ( Site 2604), Suita
National Cancer Center Hospital ( Site 2601), Tokyo
The Cancer Institute Hospital of JFCR ( Site 2605), Tokyo
CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 2900), Mexico City
Hacettepe Universitesi Tıp Fakultesi ( Site 1503), Ankara
CENEIT Oncologicos ( Site 2904), México
S.C.Focus Lab Plus S.R.L ( Site 1101), Bucharest
S.C.Gral Medical S.R.L ( Site 1104), Bucharest
Seoul National University Hospital ( Site 2401), Seoul
Severance Hospital Yonsei University Health System ( Site 2400), Seoul
Hospital Universitari Vall d Hebron ( Site 1350), Barcelona
Baskent University Adana Training Hospital ( Site 1508), Adana
Akdeniz Universitesi Tip Fakultesi ( Site 1504), Antalya
Churchill Hospital ( Site 1606), Oxford
Christie NHS Foundation Trust ( Site 1601), Manchester
Northern Centre for Cancer Care ( Site 1602), Newcastle upon Tyne
Weston Park Hospital ( Site 1607), Sheffield
Collaborators (1)
AstraZeneca
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY